Canine Atopic Dermatitis Treatment Drugs Market, By Drug Class (Janus Kinase Inhibitors, Antihistamines, Monoclonal Antibodies, Antibiotics, Allergic Immunotherapy/Desensitization Therapy, and Others), By Route of Administration (Injectable, Oral, and Topical), By Dosage Form (Tablets, Creams, Spray, and Others), By Distribution Channel (Online and Offline), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Apr 2024

Code : CMI4886

Pages :165

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges – High Cost Associated with Canine Atopic Dermatitis Treatment Drugs

The canine atopic dermatitis treatment drugs market is facing challenges due high cost associated with canine atopic dermatitis treatment drugs. Many of the medications used to treat canine AD, such as Apoquel or cyclosporine, can be expensive. These medications may need to be administered over an extended period, adding to the overall treatment cost. The high cost of medications can deter some pet owners from seeking proper treatment or limit their ability to afford long-term management, thus impacting the market growth. For instance, Cytopoint injection for dogs’ costs around US$ 50-US$ 200 per injection. This can translate to a cost of between US$ 300 and US$ 800 for a four to six-month supply. The high costs associated with canine AD treatment may lead to disparities in accessibility, with some pet owners unable to afford or access necessary treatments. Moreover, the most expensive medicines for canine atopic dermatitis are Atopica/Cyclavance/Sporimmune. A month’s course of these capsules for a medium sized dog costs around US$ 345.

Market Opportunities – Emerging Stem Cell Therapies for Canine Atopic Dermatitis

There is a strong demand for the development of new regenerative treatments for canine atopic dermatitis, which presents potential for pharmaceutical and biotechnological companies to provide new medications for the condition. Due of their immunomodulatory capabilities, mesenchymal stem cells (MSCs) are a special kind of cell that can heal tissue and organ damage brought on by autoimmune diseases or chronic inflammation. Stem cells have the ability to differentiate into different cell types and promote tissue repair and regeneration. In the context of atopic dermatitis, stem cells could potentially help regenerate damaged skin tissues and promote healing. This could lead to improved skin barrier function and reduced susceptibility to secondary infections. Additionally, stem cells can be administered locally, either through injections or topical application, directly to the affected skin areas. This localized delivery allows for targeted therapy and minimizes systemic side effects.